Zepzelca (lurbinectedin) / PharmaMar, Jazz 
Welcome,         Profile    Billing    Logout  
 26 Diseases   31 Trials   31 Trials   1838 News 


«12...6789101112131415161718»
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    [VIRTUAL] Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders () -  Sep 29, 2020 - Abstract #IASLCNACLC2020IASLC-NACLC_119;    
    However, small sample sizes preclude firm conclusions at this time. In patients with relapsed SCLC who responded to lurbinectedin, time from randomization to response was similar regardless of prior resistance or sensitivity to platinum-based chemotherapy, and clinically meaningful duration of response and survival were noted in both subgroups of responders
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    FDA event, Journal, Immunogenic cell death:  Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. (Pubmed Central) -  Sep 16, 2020   
    In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemotherapy. Thus, the clinical activity of lurbinectedin may originate, at least in part, from the induction of ICD.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal:  A scalable total synthesis of Et-743 and lurbinectedin. (Pubmed Central) -  Aug 30, 2020   
    Thus, the clinical activity of lurbinectedin may originate, at least in part, from the induction of ICD. An efficient and scalable approach for total synthesis of Et-743 and lubinectedin (about 1.6% overall yield in 26 total steps from Cbz-protected (S)-tyrosine) is described, and features the use of a common advanced intermediate to create the right and left parts of these antitumor drugs, and a light-mediated remote C-H bond activation to assemble a benzo[1,3]dioxole-embodied intermediate.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Clinical, P2 data, Journal, Pan Tumor:  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. (Pubmed Central) -  Jul 10, 2020   
    P2
    Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile. Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal:  New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer. (Pubmed Central) -  Jul 1, 2020   
    Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial. No abstract available
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Zepzelca (Twitter) -  Jun 18, 2020